Frequently Asked Questions
The global autologous cell therapy market was valued at USD 4518.9 Million in 2022.
The autologous cell therapy market is expected to grow at a CAGR of 22.3% between 2023 and 2030, reaching USD 22617.48 Million in 2030.
Mesenchymal stem cells are the leading segment by cell type, holding over 30% share in value in 2022.
The cancer treatment segment governs the global demand for autologous cell therapy, holding a massive share of over 28% in 2022.
The research institutes segment will post the highest CAGR over the projection period.
North America contributes to the robust growth of the autologous cell therapy industry, with over one-third of its market share in 2022.
The top players include BrainStorm Cell Therapeutics, Pharmicell Co. Inc, Opexa Therapeutics, Caladrius Biosciences Inc, U.S. Stem Cell Inc, Lonza, Bristol Myers Squibb, Novartis, Tego Science, Corning Incorporated, Bio Elpida, Vericel Corporation, Catalent Inc, Sartorius AG, and Others.
The major market drivers are the increased demand for personalized medicine and continuous technological advancements.
The major market restraints are the high treatment costs, regulatory challenges, and approval delays.
The major market opportunities of the autologous cell therapy industry involve expanding therapeutic applications and leveraging technological advancements to improve efficiency and scalability.